Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities

Philip A Chan, Leandro Mena, Rupa Patel, Catherine E Oldenburg, Laura Beauchamps, Amaya G Perez-Brumer, Sharon Parker, Kenneth H Mayer, Matthew J Mimiaga, Amy Nunn, Philip A Chan, Leandro Mena, Rupa Patel, Catherine E Oldenburg, Laura Beauchamps, Amaya G Perez-Brumer, Sharon Parker, Kenneth H Mayer, Matthew J Mimiaga, Amy Nunn

Abstract

Introduction: Despite the efficacy of pre-exposure prophylaxis (PrEP) in preventing HIV transmission, few studies have evaluated PrEP use and retention in care outcomes in real-world settings outside of clinical trials.

Methods: Data were collected from PrEP clinical care programmes in three mid-size US cities: Providence, Rhode Island (RI); Jackson, Mississippi (MS); and St. Louis, Missouri (MO). We assessed the demographic and social characteristics of patients prescribed PrEP and documented their insurance and copayment experiences. We assessed retention in PrEP care at three and six months. Multivariate analyses were used to predict retention in care among men who have sex with men (MSM). HIV acquisition among the cohort was also assessed.

Results: A total of 267 (RI: 117; MS: 88; MO: 62) patients were prescribed PrEP; 81% filled prescriptions (RI: 73%; MS: 82%; MO: 94%; p<0.001). Patients in MS and MO were more commonly African American than in RI (72% and 26% vs. 7%, respectively), but less frequently Latino (2% and 3% vs. 24%, respectively). More patients reported living below the federal poverty line in MS (52%) compared to MO (23%) and RI (26%). Most patients were MSM (RI: 92%; MS: 88%; MO: 84%). The majority of MSM reported recent condomless anal sex (RI: 70%; MS: 65%; MO: 75%). Among 171 patients prescribed PrEP at least six months beforehand, 72% were retained in care at three months (RI: 68%; MS: 70%; MO: 87%; p=0.12) and 57% were retained in PrEP care at six months (RI: 53%: MS: 61%; MO: 63%; p=0.51). Insurance status and medication costs were not found to be significant barriers for obtaining PrEP. Three patients became infected with HIV during the six-month period after being prescribed PrEP (1.1%; 3/267), including one in RI (suspected acute HIV infection), one in MO (confirmed poor adherence) and one in MS (seroconverted just prior to initiation).

Conclusions: PrEP initiation and retention in care differed across these distinct settings. In contrast, retention in PrEP care was consistently suboptimal across sites. Further research is needed to identify the individual, social and structural factors that may impede or enhance retention in PrEP care.

Keywords: HIV; implementation; men who have sex with men; pre-exposure prophylaxis.

Figures

Figure 1
Figure 1
Retention in HIV pre-exposure prophylaxis (PrEP) care cascade overall and for Rhode Island, Mississippi and Missouri. Blue bars indicated the number of patients who received a prescription for PrEP (and had been in the programme for six or more months), red bars indicate the number who initiated PrEP (confirmed to have started the medication), green bars indicate the number who were retained in PrEP care at three months and purple bars indicate the number who were retained in PrEP care at six months.

References

    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.
    1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
    1. Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.
    1. Grant RM, Anderson PL, McMahan V, Liu AY, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. Elsevier Ltd. 2014;14(9):820–9.
    1. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.
    1. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.
    1. King HL, Keller SB, Giancola MA, Rodriguez DA, Chau JJ, Young JA, et al. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study) AIDS Behav. 2014;18(9):1722–5.
    1. Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. Vermund SH, editor. PLoS One. 2012;7(3):e33119.
    1. Volk J, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1–10.
    1. Liu A, Cohen S, Follansbee S, Cohan D, Weber S, Sachdev D, et al. Early experiences implementing pre-exposure prophylaxis (PrEP) for HIV prevention in San Francisco. PLoS Med. 2014;11(2):e1001613.
    1. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2015:1–11.
    1. Parker S, Chan PA, Oldenburg CE, Hoffmann M, Poceta J, Harvey J, et al. Patient experiences of men who have sex with men using pre-exposure prophylaxis to prevent HIV infection. AIDS Patient Care STDS. 2015;29(12):639–42.
    1. Chen Y-H, Snowden JM, McFarland W, Raymond HF. Pre-exposure prophylaxis (PrEP) use, Seroadaptation, and sexual behavior among men who have sex with men, San Francisco, 2004–2014. Springer US. 2016:1–7. [Epub ahead of print]
    1. Wheeler DP, Fields S, Nelson LE, Wilton L, Hightow-Weidman L, Shoptaw S, et al. HPTN 073: PrEP uptake and use by black men who have sex with men in 3 US cities. Conference on Retroviruses and Opportunistic Infections; Boston, MA. 2016.
    1. Koester K, Grant RM. Keeping our eyes on the prize: no new HIV infections with increased use of HIV pre-exposure prophylaxis. Clin Infect Dis. 2015;61(10):1–5.
    1. HIV TL. PrEP: why are we waiting? Lancet HIV. Elsevier Ltd. 2015;2(10):e401.
    1. Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013;27(4):248–54.
    1. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77–83.
    1. Mimiaga MJ, Closson EF, Kothary V, Mitty JA. Sexual partnerships and considerations for HIV antiretroviral pre-exposure prophylaxis utilization among high-risk substance using men who have sex with men. Arch Sex Behav. 2013;43(1):99–106.
    1. Cohen SE, Vittinghoff E, Bacon O, Doblecki-Lewis S, Postle BS, Feaster DJ, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr. 2015;68(4):439–48.
    1. Smith DK, Koenig LJ, Martin M, Mansergh G, Heneine W, Ethridge SF, et al. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2014 clinical practice guidelines. Washington, DC: US Public Health Service; 2014. Atlanta, GA: Centers for Disease Control and Prevention.
    1. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-Tenofovir Concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151) 151ra125–5.
    1. Mississippi Division of Medicaid [Internet] [cited 2015 Jan 12]. Available from:
    1. : Rhode Island [Internet] [cited 2015 Jan 12]. Available from: .
    1. Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of Serodiscordant couples in East Africa. Siegfried N, editor. PLoS Med. 2013;10(9):e1001511.
    1. Oldenburg CE, Perez-Brumer AG, Hatzenbuehler ML, Krakower D, Novak DS, Mimiaga MJ, et al. State-level structural sexual stigma and HIV prevention in a national online sample of HIV-uninfected MSM in the United States. AIDS. 2015;29:837–45.
    1. Nunn A, Yolken A, Cutler B, Trooskin S, Wilson P, Little S, et al. Geography should not Be Destiny: focusing HIV/AIDS implementation research and programs on microepidemics in US neighborhoods. Am J Public Health. 2014;104:775–80.
    1. Oldenburg CE, Perez-Brumer AG, Reisner SL. Poverty matters: contextualizing the syndemic condition of psychological factors and newly diagnosed HIV infection in the United States. AIDS. 2014;28(18):2763–9.
    1. Centers for Disease Control and Prevention. Characteristics associated with HIV infection among heterosexuals in Urban areas with high AIDS prevalence – 24 Cities, United States, 2006–2007. MMWR Recomm Rep. 2011;60(31):1045–9.
    1. The Patient Protection and Affordable Care Act (PPACA) 2010. Mar pp. Pub.L.No.111–148–124Stat.119. Report No.: Pub. L. No. 111-148, 124 Stat. 119.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir